Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000705555 | SCV000834556 | pathogenic | Imerslund-Grasbeck syndrome | 2023-10-05 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg1810*) in the CUBN gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CUBN are known to be pathogenic (PMID: 15024727, 22929189, 25349199, 31613795, 34979989). This variant is present in population databases (rs143944436, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with clinical features of Imerslund-Gräsbeck syndrome (PMID: 31613795). ClinVar contains an entry for this variant (Variation ID: 581662). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV001536070 | SCV001752767 | pathogenic | Imerslund-Grasbeck syndrome type 1; Proteinuria, chronic benign | 2024-02-14 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001547777 | SCV001767560 | likely pathogenic | not provided | 2024-12-16 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25635822, 31589614, 35064937, 31613795, 38287090) |
Revvity Omics, |
RCV001547777 | SCV002019781 | pathogenic | not provided | 2023-06-19 | criteria provided, single submitter | clinical testing | |
Sing |
RCV000705555 | SCV000853127 | likely pathogenic | Imerslund-Grasbeck syndrome | 2017-06-07 | no assertion criteria provided | curation | |
Bioscientia Institut fuer Medizinische Diagnostik Gmb |
RCV000705555 | SCV000863860 | likely pathogenic | Imerslund-Grasbeck syndrome | 2018-05-09 | no assertion criteria provided | clinical testing | |
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV001547777 | SCV002037528 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001547777 | SCV002037905 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Gene Friend Way, |
RCV003313972 | SCV004013903 | likely pathogenic | Autism spectrum disorder | 2023-07-28 | no assertion criteria provided | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease. In our study, two children diagnosed with severe Autism Spectrum Disorder (ASD) are carriers of this mutation, among the two patients, one also carries another variant known to associate with ASD (SRD5A2 (rs9332964)). |
Prevention |
RCV003918139 | SCV004727822 | pathogenic | CUBN-related disorder | 2023-11-29 | no assertion criteria provided | clinical testing | The CUBN c.5428C>T variant is predicted to result in premature protein termination (p.Arg1810*). This variant was reported with a second CUBN variant in two patients with kidney disease; however, phase of the variants was not determined (Supp. Table 2 in Bedin et al. 2020. PubMed ID: 31613795). Of note, the c.5428C>T has been reported with the c.6088C>T (p.Arg2030*) variant in two patients in the literature, but segregation analysis was not completed to determine phase (Family 21, Supp Table 2 in Bedin et al. 2020. PubMed ID: 31613795; Case #20, Supp. Table 3 in Lu L et al 2022. PubMed ID: 35064937). At PreventionGenetics, we have observed the c.6088C>T and c.5428C>T variants to occur on the same allele (cis phase) based on parental follow up testing (internal data). This variant is reported in 0.024% of alleles in individuals of African descent in gnomAD. Nonsense variants in CUBN are expected to be pathogenic. This variant is interpreted as pathogenic. |